论文部分内容阅读
选取54例血糖控制良好的糖尿病合并高脂血症患者,随机分为两组。对照组26例,给予瑞舒伐他10mg,每日1次;治疗组28例,给依折麦布与瑞舒伐他汀各10mg,每日1次。以总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)为参数,3个月后比较两组治疗前后血脂谱水平。结果:两组的总胆固醇、甘油三酯、低密度脂蛋白胆固醇均较治疗前有显著下降(P<0.05),且治疗组较对照组明显(P<0.01),高密度脂蛋白胆固醇较治疗前显著升高(P<0.05)。治疗组各项指标变化与对照组比较差异有统计学意义(P<0.05)。结论:依折麦布联合瑞舒伐他汀较单用瑞舒伐他汀能更有效地改善糖尿病患者的血脂谱,是一种理想的降脂方案。
Fifty-four patients with well-controlled diabetes and hyperlipidemia were randomly divided into two groups. Control group, 26 cases, given rosuvastatin 10mg, 1 day; treatment group 28 cases, to ezetimibe and rosuvastatin 10mg, 1 times a day. The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL- . Results: The levels of total cholesterol, triglyceride and low density lipoprotein cholesterol in both groups were significantly lower than those before treatment (P <0.05), and were significantly higher in the treatment group than those in the control group (P <0.01). High density lipoprotein cholesterol Before significant increase (P <0.05). The treatment group indicators change compared with the control group was statistically significant (P <0.05). Conclusion: Ezetimibe combined with rosuvastatin can improve blood lipid profile of diabetic patients more effectively than rosuvastatin alone, which is an ideal lipid-lowering regimen.